Want to join the conversation?
Provider of investment management and advisory services $EV said that although it continues to maintain positive organic growth, the market movement, seasonal FX and lower average fee rates driven mainly by changes in product mix, pushed revenues lower in 2Q16. This resulted in a decline in earnings during the quarter.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.